The engineered cord endothelial cell (E-CEL) product AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation (HDT-ASCT). Interim results of the phase 1b/2 AB-205-001 trial (NCT03925935), presented during the 47th Annual Meeting of The European Society for Blood and Marrow Transplantation, showed AB-205 to be particularly effective in eliminating oral/ gastrointestinal (GI) severe regimen-related toxicities (SRRT) for these patients.
Overall, the agent was found to be well tolerated with no clinically significant infusion-related reactions. The adverse events (AEs) reported on study were consistent with that in an AHCT population, and the maximum-tolerated dose was not reached, explained lead study author Carolyn Mulroney, MD, in a presentation during the meeting.
AB-205 has significant potential to address a serious unmet need in patients undergoing HDTAHCT, said Mulroney, a hematologist/medical oncologist and associate professor of medicine at University of California San Diego Health. This drug has been granted orphan drug designation by the FDA. The highest dose of 20 106 E-CEL/kg demonstrated robust effect in eliminating oral/GI severe regimen-related toxicities.
HDT-AHCT is potentially curative for patients with high-risk, chemotherapy-sensitive lymphomas. However, HDT not only eradicates malignant cells but also can cause severe injury to healthy tissues via vascular endothelial damage. Some of these are SRRT, which lead to high symptom burden and life-threatening organ toxicities. The risk of these SRRTs could make select patients, particularly older patients, ineligible for AHCT.
Moreover, although hematopoiesis is largely rescued by AHCT, there are no effective treatments to repair endothelial damage, Mulroney explained.
AB-205 is an off-the-self E-CEL product comprised of allogeneic human E4CD31 umbilical endothelial cells. These engineered cells can respond to cytokines produced by damaged cells and release angiocrine factors that act via juxtacrine and paracrine mechanisms and support microvasculature repair through interactions with intact endothelial cells.
Data from preclinical models demonstrated that AB-205 restores the natural healing process of the marrow, spleen, and GI tract and that it also accelerates hematopoietic recovery and increases survival following LD50 radiation.
In the phase 1 dose-escalation study (NCT03925935), investigators enrolled patients with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma undergoing their first hematopoietic stem cell transplant who were eligible for HDT-AHCT and had an ECOG performance status of 0 to 1. Localized radiation and posttransplant maintenance were permitted.
Cohorts were enrolled sequentially following safety assessment of the previous cohort. Doses by cohort (FIGURE1 ) were as follows: cohort 1 (5 106 E-CEL/kg on day 0), cohort 2 (10 106 E-CEL/kg on day 0), cohort 3 (20 106 E-CEL/kg on day 0), and cohort 4 (20 106 E-CEL/kg in a split dose of 50% on day 0 and the remaining 50% on day 2).
AB-205 was administered intravenously, and high-dose therapy regimens consisted of carmustine, etoposide, cytarabine, and melphalan (BEAM); bendamustine, etoposide, cytarabine, and melphalan (BeEAM); cyclophosphamide, carmustine, and etoposide (CBV); and thiotepa, busulfan, and cyclophosphamide (TBC).
The primary end point was safety; secondary end points included severity and duration of grade 3 or higher oral/GI toxicities, and time to neutrophil and platelet engraftment. Exploratory outcome measures were progression-free survival (PFS), nonrelapse mortality, overall survival (OS), and lymphoid recovery.
To establish a modern historical control concurrent with study enrollment, a chart review was concurrently conducted of 45 consecutive patients undergoing AHCT for systemic lymphoma. Patients received conditioning with HDT with BEAM, BeEAM, or CBV from 2019 to 2020.
Baseline characteristics were stratified between 2 dose ranges of AB-205 (< 20 106 E-CEL/kg and 20 106 E-CEL/kg) and the chart review cohort. In total, the median age was 56.6 years, and 37.6% of patients were younger than 60 years. Sixty-two percent of patients were male, and 71% had been diagnosed with NHL. The median number of prior therapies was 2, HDT regimens were BEAM (87.6%), BeEAM (9.3%), and CBV (3%). The median CD34+ count was 4.56 106 /kg.
The median duration of follow-up was 8.1 months (range, 3.7-16.6), and no deaths occurred in the 29 patients. One patient with stage IV diffuse large B-cell lymphoma who had a partial response, relapsed at day 101.
No evidence suggested that AB-205 had a detrimental effect on either PFS or OS, Mulroney said.
Safety data were evaluable for 29 patients with systemic lymphomas. Treatment-emergent AEs and serious AEs occurred in 31% of patients. Additionally, 1 dose-limiting toxicity, which was prolonged thrombocytopenia (> 28 days), was observed during dose escalation (at 10 106 E-CEL/kg-dose) and was unrelated to study treatment.
In patients receiving less than 20 106 E-CEL/kg (n= 11), AEs were hypokalemia, oral mucositis, supraventricular tachycardia, upper respiratory infection, and epistaxis (9% each; n=1 each). In patients receiving 20 106 E-CEL/kg (n=18), 11% experienced hypokalemia and 6% experienced angina pectoris, sepsis, enterocolitis infectious, depression, hyperkalemia, hypocalcemia, dehydration, or hypertension (n=1 each).
The clinically meaningful end point of oral/GI SRRT, which was defined as grade 3 or higher oral mucositis, nausea/vomiting, or diarrhea, was also evaluated. Low rates of this SRRT were reported with the less than 20 106 E-CEL/kg dose (9%) and the 20 106 E-CEL/kg dose (0%) compared with the control cohort (60%).
Oral/GI regimen-related toxicities, defined as all-grade events, were experienced at lower rates with AB-205 at the less than 20 106 E-CEL/kg and 20 106 E-CEL/kg doses in regard to oral mucositis (64% and 50%, respectively), nausea/vomiting (64% and 28%), and diarrhea (82% and 50%). The control cohorts were 69%, 89%, and 82%, respectively.
Investigators also evaluated time to neutrophil and platelet engraftment. The median time to neutrophil engraftment was 10 days, the median time to platelet engraftment was 11 days, and the rate of platelet engraftment within 1 day of neutrophil engraftment was 69%. The median time to discharge from AHCT was 12 days.
Mulroney added that these data were the basis for the FDAs regenerative medicine advanced therapy designation, and the findings were the subject of an end-of-phase-2 meeting with the regulatory agency. A pivotal, double-blind, placebo-controlled, randomized study for potential registration of AB-205 is planned for US and European sites.
References:
Mulroney C, Scordo M, Abedi M, et al. Open label dose escalation trial of AB-205 (E-CEL cells) in adults with systemic lymphoma undergoing highdose therapy and autologous hematopoietic cell transplantation (HDTAHCT). Presented at: European Society for Blood and Marrow Transplantation 47th Annual Meeting; March 14-17, 2021; virtual. Abstract OS5-5.
Continue reading here:
AB-205 Shows Promise in Patients With Systemic Lymphoma Undergoing HDT-ASCT - Targeted Oncology
- Embattled Cordlife receives letter of demand from client for breach of contract - The Straits Times - May 4th, 2024
- From Cord Blood to Microbiome; The evolution of Rotary's gift to the people of WA - Lifeblood - May 2nd, 2024
- Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune ... - Nature.com - April 28th, 2024
- Hitting the pavement for cord blood research | Cranbourne Star News - Cranbourne Star News - April 28th, 2024
- One year to test 200 Cordlife samples 'totally unjustified': Global cord blood banking experts - The Straits Times - April 15th, 2024
- Clinical trial: First cardiac bioimplants for treatment of myocardial infarction using umbilical cord stem cells - Medical Xpress - April 7th, 2024
- The umbilical cord: a rich and ethical stem cell source to advance ... - March 30th, 2024
- Story of discovery: getting a Notch up on cord blood cell ... - March 30th, 2024
- Cord Blood Transplants | Memorial Sloan Kettering Cancer Center - March 30th, 2024
- Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel ... - Nature.com - March 17th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024: The Vast Majority of the Global Cord Blood Market is Now ... - PR Newswire - March 15th, 2024
- Improving Transplant Outcomes and Cell Therapy Approaches - RegMedNet - March 9th, 2024
- The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute ... - ScienceDirect.com - March 1st, 2024
- Beating Blood Cancer through Recycling - a Community crowdfunding project in Liverpool by Kate Williams - Crowdfunder UK - February 24th, 2024
- Cord Blood Registry (CBR ) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing - Investing.com Canada - February 9th, 2024
- Young cancer patient with 'no hope' of recovery saved by baby's umbilical cord - Study Finds - February 9th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN - January 26th, 2024
- Finding the optimal combination of anticancer drug administration for the conditioning of cord blood transplantation - Medical Xpress - January 26th, 2024
- Cord Blood Banking Market Sales and Revenue Report 2023-2032 - WhaTech Technology and Markets News - January 26th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN USA - January 24th, 2024
- Global Biobanking Market Size To Exceed USD 97.5 Billion By 2032 | CAGR of 5.8% - GlobeNewswire - January 24th, 2024
- The use of cryopreservation in life saving research - The Manufacturer - January 24th, 2024
- CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies - Medical Xpress - January 18th, 2024
- Cord blood banking comes at a high cost to babies - STAT - STAT - January 18th, 2024
- Global Cord Blood and Tissue Banking Industry Gains Traction Amidst Surging M&A Activity and Technological Advances - PR Newswire - January 16th, 2024
- Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering - January 11th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 4th, 2024
- askST: Can cord blood units be transferred from one bank to another? - The Straits Times - December 27th, 2023
- Timeline: Cordlife's mishandling of cord blood units in Singapore - CNA - December 15th, 2023
- Next-Level Evolution: Enhancing the Human Body With Anthrobots ... - Securities.io - December 5th, 2023
- Fred Hutch at ASH: Gene therapies for sickle cell, how to improve ... - Fred Hutchinson Cancer Center - December 5th, 2023
- Enhancing the immunosuppressive properties of human umbilical ... - Phys.org - December 1st, 2023
- Global Status and Trends for Thromboangiitis Obliterans | JPR - Dove Medical Press - December 1st, 2023
- Early Stage Cell Therapy Trial Shows Promise in Treating Progressive Multiple Sclerosis - University of Colorado Anschutz Medical Campus - December 1st, 2023
- Global Medical Specialty Bag Market is Expected to Reach US$ 9.4 Billion by 2034, Rising at a Steady 4.7% CAGR | Future Market Insights, Inc. - Yahoo... - November 29th, 2023
- Repeated concussions can alter heart activity and impact the heart ... - Philippine Canadian Inquirer - November 29th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - PharmiWeb.com - November 27th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - Marketscreener.com - November 25th, 2023
- FY 2021 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- New study aims to expand access to stem cell transplant using ... - Healio - November 23rd, 2023
- Impact of GVHD Prophylaxis on CMV Reactivation and Disease ... - Cancer Network - November 23rd, 2023
- The Top 25 Women Leaders in Biotechnology of 2023 - The Healthcare Technology Report. - November 21st, 2023
- First Edition: November 20, 2023 - KFF Health News - November 21st, 2023
- An essential guide to the building blocks of life - Gates Notes - November 21st, 2023
- A Simple Way to Save Premature Babies - The New York Times - November 19th, 2023
- Perspectives of current understanding and therapeutics of Diamond ... - Nature.com - November 17th, 2023
- Brain Organoids: Should They Be Considered People? - BBVA OpenMind - November 17th, 2023
- Understanding the cause of childhood Alzheimer's - ASBMB Today - November 17th, 2023
- Peripheral nerve regeneration through nanofiber scaffolds | IJN - Dove Medical Press - November 15th, 2023
- Are STEM CELL EXOSOMES the secret to a 'snatched' jawline? Discover the products that influencers are claiming - Daily Mail - November 13th, 2023
- CAR-NK: The next generation in hematological malignancy treatment - News-Medical.Net - November 13th, 2023
- Regenerative Medicine | Top Regenerative Medicine Solution ... - Healthcare Tech Outlook - November 13th, 2023
- Stem cell therapy, emerging solution to slow down ageing - Punch Newspapers - November 13th, 2023
- Improving Cord Blood Transplantation Outcomes for Adults With ... - On Cancer - Memorial Sloan Kettering - November 11th, 2023
- 8 Ways To Save Lives With Canadian Blood Services & You Can ... - Narcity Canada - November 11th, 2023
- Internal investigation by Vita 34 AG reveals irregularities related to a ... - Marketscreener.com - November 11th, 2023
- 'We worried the worst would happen' - Yorkshire Children's Trust ... - The Yorkshire Post - November 11th, 2023
- Minor GPI(-) granulocyte populations in aplastic anemia and healthy ... - Nature.com - November 9th, 2023
- Repeated treatment with ProTrans is immunologically safe ... - Marketscreener.com - November 7th, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells - Benzinga - November 7th, 2023
- Health Canada issues warning on cord blood stored in Edmonton - CBC News - November 3rd, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting - Yahoo... - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance ... - InvestorsObserver - November 3rd, 2023
- Go with the flow and achieve hearing restoration - Drug Discovery News - November 3rd, 2023
- Cell Therapy Market to Witness Exponential Growth by 2031 ... - Argyle Report - November 1st, 2023
- Cross-talk between Myeloid and B Cells Shapes the Distinct ... - Cancer Discovery - November 1st, 2023
- Comparison of effects of HucMSCs, exosomes, and conditioned ... - Nature.com - October 28th, 2023
- The structural and functional complexity of the integrative ... - Science - October 28th, 2023
- Global Primary Cells Market to Witness Growth at 11.41% CAGR to ... - GlobeNewswire - October 26th, 2023
- Hma-Qubec celebrates 25 years of giving life in anniversary ad - - The Message - October 26th, 2023
- Improvement of thermal-stability of chondroitinase ABCI immobilized ... - Nature.com - October 26th, 2023
- Sydney Couple Overcomes Sperm Antibody Issue to Welcome Baby - OPP.Today - October 24th, 2023
- New Research Reveals Surprising Issue with Sperm and Fertility - CityLife - October 24th, 2023
- Biobanking Market to Observe Prominent CAGR of 6.10% by 2029 ... - PharmiWeb.com - October 21st, 2023
- TV shows like BBC's Call The Midwife and C4's One Born Every Minute 'are inaccurately depicting childbirth' an - Daily Mail - October 19th, 2023
- Advances in medical and technological research and SCI - Clyde & Co - October 18th, 2023
- Prognostic Value of Hematogones in Patients With Hematopoietic ... - Cureus - October 18th, 2023
- Stem-Cell Therapy: Filling Gaps in Oro-Maxillofacial Region - Cureus - October 18th, 2023
- The neonatal southern white rhinoceros ovary contains oogonia in ... - Nature.com - October 18th, 2023
- OMG: Sperm injury led to rare baby struggle - news.com.au - October 18th, 2023
Recent Comments